These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1061 related items for PubMed ID: 20195219

  • 21. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, Sirolimus Renal Function Study Group.
    Transplantation; 2002 Dec 15; 74(11):1560-7. PubMed ID: 12490789
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.
    Clin J Am Soc Nephrol; 2012 Mar 15; 7(3):504-12. PubMed ID: 22282478
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation.
    Knight RJ, Kerman RH, Zela S, Podder H, Van Buren CT, Katz S, Kahan BD.
    Transplantation; 2003 Apr 27; 75(8):1301-6. PubMed ID: 12717220
    [Abstract] [Full Text] [Related]

  • 32. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF, Mahmoud KM, Ismail AM, Sheashaa HA, Kamal AI, Ghoneim MA.
    Exp Clin Transplant; 2011 Oct 27; 9(5):295-301. PubMed ID: 21967254
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U, 2411 Study Investigators.
    Transplantation; 2009 Jul 15; 88(1):115-22. PubMed ID: 19584690
    [Abstract] [Full Text] [Related]

  • 36. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation.
    Alexander JW, Goodman HR, Cardi M, Austin J, Goel S, Safdar S, Huang S, Munda R, Fidler JP, Buell JF, Hanaway M, Susskind B, Roy-Chaudhury P, Trofe J, Alloway R, Woodle ES.
    Transpl Int; 2006 Apr 15; 19(4):295-302. PubMed ID: 16573545
    [Abstract] [Full Text] [Related]

  • 37. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
    Thierry A, Le Meur Y, Ecotière L, Abou-Ayache R, Etienne I, Laurent C, Vuiblet V, Colosio C, Bouvier N, Aldigier JC, Rerolle JP, Javaugue V, Gand E, Bridoux F, Essig M, Hurault de Ligny B, Touchard G.
    Transpl Int; 2016 Jan 15; 29(1):23-33. PubMed ID: 26729582
    [Abstract] [Full Text] [Related]

  • 38. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Jul 27; 76(2):364-70. PubMed ID: 12883194
    [Abstract] [Full Text] [Related]

  • 39. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 40. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.
    Guba M, Pratschke J, Hugo C, Krämer BK, Pascher A, Pressmar K, Hakenberg O, Fischereder M, Brockmann J, Andrassy J, Banas B, Jauch KW, SMART-Study Group.
    Transpl Int; 2012 Apr 20; 25(4):416-23. PubMed ID: 22320241
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.